Cancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin

Author： Dunbar S.D.   Ornstein D.L.   Zacharski L.R.  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.9, Iss.9, 2000-09, pp. : 2085-2092

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhibitors of the Protease Domain of Urokinase-Type Plasminogen Activator

By  

Current Pharmaceutical Design, Vol. 8, Iss. 28, 2002-12 ,pp. : 2541-2558

Bentham Science Publishers

Access to resources Recommend Favorite

Small molecule inhibitors of urokinase-type plasminogen activator

By Rockway Todd W  

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 6, 2003-06 ,pp. : 773-786

Informa Healthcare

Access to resources Recommend Favorite

The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling

By  

Current Pharmaceutical Design, Vol. 17, Iss. 19, 2011-06 ,pp. : 1944-1961

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibitors of the Proteolytic Activity of Urokinase Type Plasminogen Activator

By  

Current Pharmaceutical Design, Vol. 9, Iss. 19, 2003-07 ,pp. : 1483-1498

Bentham Science Publishers

Access to resources Recommend Favorite

New developments in the urokinase-type plasminogen activator system

By Rosenberg Steven  

Expert Opinion on Therapeutic Targets, Vol. 5, Iss. 6, 2001-12 ,pp. : 711-722

Informa Healthcare

Access to resources Recommend Favorite